

Chapter 111

Chemical Carcinogenesis

Adam B. Glick & Andrzej A. Dlugosz

REFERENCES

1. Jemal A et al: Cancer statistics, 2010. *CA Cancer J Clin* **60**:277, 2010
2. Rogers HW et al: Incidence estimate of nonmelanoma skin cancer in the United States, 2006. *Arch Dermatol* **146**:283, 2010
3. Pott P: Cancer scrotic. In: *Chirurgical Observations Relative to the Cataract, the Polypus of the Nose, the Cancer of the Scrotum, the Different Kinds of Ruptures, and the Mortification of the Toes and Feet*. London, Hawes, Clarke, and Collins, 1775, p. 63
4. Gallagher RP et al: Chemical exposures, medical history, and risk of squamous and basal cell carcinoma of the skin. *Cancer Epidemiol Biomarkers Prev* **5**:419, 1996
5. De Hertog S et al: Relation between smoking and skin cancer. *J Clin Oncol* **19**:231, 2001
6. Tapio S, Grosche B: Arsenic in the aetiology of cancer. *Mutat Res* **612**:215, 2006
7. Brown KG et al: A dose-response analysis of skin cancer from inorganic arsenic in drinking water. *Risk Analysis* **9**:519, 1989
8. Rossman TG et al: Arsenite is a cocarcinogen with solar ultraviolet radiation for mouse skin: An animal model for arsenic carcinogenesis. *Toxicol Appl Pharmacol* **176**:64, 2001
9. Burns FJ et al: Arsenic-induced enhancement of ultraviolet radiation carcinogenesis in mouse skin: A dose-response study. *Environ Health Perspect* **112**:599, 2004
10. Penn I: Post-transplant malignancy: The role of immunosuppression. *Drug Saf* **23**:101, 2000
11. O'Donovan P et al: Azathioprine and UVA light generate mutagenic oxidative DNA damage. *Science* **309**:1871, 2005
12. Yarosh DB et al: Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. *J Invest Dermatol* **125**:1020-1025, 2005
13. Vonderheid EC et al: Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. *J Am Acad Dermatol* **20**(3):416-428, 1989 PubMed PMID: 2537348.
14. Roelofzen JH et al: No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. *J Invest Dermatol* **130**:953, 2010
15. Lichter MD et al: Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group. *Arch Dermatol* **136**:1007, 2000
16. Stern RS, Liebman E, Vakeva L: Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. *J Natl Cancer Inst* **90**:1278, 1998
17. Stern RS: Genital tumors among men with psoriasis exposed to psoralen and ultraviolet A radiation (PUVA) and ultraviolet B radiation. *N Engl J Med* **322**:1093, 1990
18. Stern RS, Nichols KT, Väkevä LH: Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. *N Engl J Med* **336**:1041-1045, 1997
19. Stern RS: Putting iatrogenic risk in perspective: basal cell cancer in PUVA patients and Australians. *J Invest Dermatol* **129**:2315-2316, 2009
20. Nataraj AJ, Black HS, Ananthaswamy HN: Signature p53 mutation at DNA cross-linking sites in 8-methoxypsoralen and ultraviolet A (PUVA)-induced murine skin cancers. *Proc Natl Acad Sci USA* **93**:7961, 1996
21. Harwood CA et al: Detection of human papillomavirus DNA in PUVA-associated non-melanoma skin cancers. *J Invest Dermatol* **111**:123, 1998
22. Lee E, Koo J, Berger T: UVB phototherapy and skin cancer risk: A review of the literature. *Int J Dermatol* **44**:355, 2005
23. Schulman JM, Fisher DE: Indoor ultraviolet tanning and skin cancer: health risks and opportunities. *Curr Opin Oncol* **21**:144-149, 2009
24. El Ghissassi F et al: A review of human carcinogens—part D: radiation. *Lancet Oncol* **10**:751-752, 2009

25. Fisher DE, James WD: Indoor tanning—science, behavior, and policy. *N Engl J Med* **363**(10):901-903, 2010
26. Luch A: Nature and nurture—Lessons from chemical carcinogenesis. *Nat Rev Cancer* **5**:113, 2005
27. Dipple A: DNA adducts of chemical carcinogens. *Carcinogenesis* **16**:437, 1995
28. Jackson MA, Stack HF, Waters MD: The genetic toxicology of putative nongenotoxic carcinogens. *Mutat Res* **296**:241, 1993
29. Marnett LJ: Oxyradicals and DNA damage. *Carcinogenesis* **21**:361, 2000
30. Yuspa SH, Shields, PG: Etiology of cancer: Chemical factors. In: *Cancer Principles of Oncology*, 5th edition, edited by VT DeVita et al. Philadelphia, Lippincott-Raven, 1997, p. 185
31. Gonzalez F: Genetic polymorphism and cancer susceptibility: Fourteenth Sapporo Cancer Seminar. *Cancer Res* **55**:710, 1995
32. Nebert DW, Dalton TP: The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. *Nat Rev Cancer* **6**:947, 2006
33. Ioannides C, Lewis DF: Cytochromes P450 in the bioactivation of chemicals. *Curr Top Med Chem* **4**:1767, 2004
34. Bock KW, Kohle C: The mammalian aryl hydrocarbon (Ah) receptor: From mediator of dioxin toxicity toward physiological functions in skin and liver. *Biol Chem* **390**:1225, 2009
35. Croce CM: Oncogenes and cancer. *N Engl J Med* **358**:502, 2008
36. Foulkes WD: Inherited susceptibility to common cancers. *N Engl J Med* **359**:2143, 2008
37. Somoano B, Niendorf KB, Tsao H: Hereditary cancer syndromes of the skin. *Clin Dermatol* **23**:85, 2005
38. van Steeg H, Kraemer KH: Xeroderma pigmentosum and the role of UV-induced DNA damage in skin cancer. *Mol Med Today* **5**:86, 1999
39. Cleaver JE: Cancer in xeroderma pigmentosum and related disorders of DNA repair. *Nat Rev Cancer* **5**:564, 2005
40. de Boer J, Hoeijmakers JH: Nucleotide excision repair and human syndromes. *Carcinogenesis* **21**:453, 2000
41. Wei Q et al: DNA repair related to multiple skin cancers and drug use. *Cancer Res* **54**:437, 1994
42. Wood RD et al: Human DNA repair genes. *Science* **291**:1284, 2001
43. Winsey SL et al: A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer. *Cancer Res* **60**:5612, 2000
44. Daya-Grosjean L, Sarasin A: The role of UV induced lesions in skin carcinogenesis: An overview of oncogene and tumor suppressor gene modifications in xeroderma pigmentosum skin tumors. *Mutat Res* **571**:43, 2005
45. Saran A: Basal cell carcinoma and the carcinogenic role of aberrant Hedgehog signaling. *Future Oncol* **6**:1003, 2010
46. Barakat MT, Humke EW, Scott MP: Learning from Jekyll to control Hyde: Hedgehog signaling in development and cancer. *Trends Mol Med* **16**:337, 2010
47. Hussussian CJ et al: Germline p16 mutations in familial melanoma. *Nat Genet* **8**:15, 1994
48. Davies H et al: Mutations of the BRAF gene in human cancer. *Nature* **417**:949, 2002
49. Liaw D et al: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. *Nat Genet* **16**:64, 1997
50. Li J et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science* **275**:1943, 1997
51. Bapat B et al: The genetic basis of Muir-Torre syndrome includes the hMLH1 locus. *Am J Hum Genet* **59**:736, 1996
52. Bignell GR et al: Identification of the familial cylindromatosis tumour-suppressor gene. *Nat Genet* **25**:160, 2000
53. Salhi A et al: Multiple familial trichoepithelioma caused by mutations in the cylindromatosis tumor suppressor gene. *Cancer Res* **64**:5113, 2004
54. Nickerson ML et al: Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. *Cancer Cell* **2**:157, 2002
55. Chan EF et al: A common human skin tumour is caused by activating mutations in beta-catenin. *Nat Genet* **21**:410, 1999
56. Takeda H et al: Human sebaceous tumors harbor inactivating mutations in LEF1. *Nat Med* **12**:395, 2006
57. Dlugosz A, Merlino G, Yuspa SH: Progress in cutaneous cancer research. *J Invest Dermatol Symp Proc* **7**:17, 2002

58. Oro AE et al: Basal cell carcinomas in mice overexpressing sonic hedgehog. *Science* **276**:817, 1997
59. Adolphe C et al: An in vivo comparative study of sonic, desert and Indian hedgehog reveals that hedgehog pathway activity regulates epidermal stem cell homeostasis. *Development* **131**:5009, 2004
60. Xie J et al: Activating Smoothed mutations in sporadic basal-cell carcinoma. *Nature* **391**:90, 1998
61. Grachtchouk V et al: The magnitude of hedgehog signaling activity defines skin tumor phenotype. *EMBO J* **22**:2741, 2003
62. Fan H et al: Induction of basal cell carcinoma features in transgenic human skin expressing Sonic Hedgehog. *Nat Med* **3**:788, 1997
63. Goodrich LV et al: Altered neural cell fates and medulloblastoma in mouse patched mutants. *Science* **277**:1109, 1997
64. Hahn H et al: Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. *Nat Med* **4**:619, 1998
65. Aszterbaum M et al: Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. *Nat Med* **5**:1285, 1999
66. Mancuso M et al: Basal cell carcinoma and its development: Insights from radiation-induced tumors in Ptch1-deficient mice. *Cancer Res* **64**:934, 2004
67. Nilsson M et al: Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. *Proc Natl Acad Sci U S A* **97**:3438, 2000
68. Grachtchouk M et al: Basal cell carcinomas in mice overexpressing Gli2 in skin. *Nat Genet* **24**:216, 2000
69. Hutchin ME et al: Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: Conditional skin tumorigenesis recapitulates the hair growth cycle. *Genes Dev* **19**:214, 2005
70. Smoller BR: Squamous cell carcinoma: From precursor lesions to high-risk variants. *Mod Pathol* **19(Suppl 2)**:S88, 2006
71. Khavari PA: Modelling cancer in human skin tissue. *Nat Rev Cancer* **6**:270, 2006
72. Lazarov M et al: CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. *Nat Med* **8**:1105, 2002
73. Dajee M et al: NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. *Nature* **421**:639, 2003
74. Friedberg EC, Meira LB: Database of mouse strains carrying targeted mutations in genes affecting cellular responses to DNA damage. Version 4. *Mutat Res* **459**:243, 2000
75. Ise K et al: Targeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis. *Oncogene* **19**:2951, 2000
76. Quintanilla M et al: Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. *Nature* **322**:78, 1986
77. Brown K et al: The malignant capacity of skin tumours induced by expression of a mutant H-ras transgene depends on the cell type targeted. *Curr Biol* **8**:516, 1998
78. Perez-Losada J, Balmain A: Stem-cell hierarchy in skin cancer. *Nat Rev Cancer* **3**:434, 2003
79. Kemp CJ et al: Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. *Cell* **74**:813, 1993
80. Ahmadian A et al: Genetic instability in the 9q22.3 region is a late event in the development of squamous cell carcinoma. *Oncogene* **17**:1837, 1998
81. Krimpenfort P et al: Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. *Nature* **413**:83, 2001
82. Sotillo R et al: Invasive melanoma in Cdk4-targeted mice. *Proc Natl Acad Sci U S A* **98**:13312, 2001
83. Dankort D et al: Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. *Nat Genet* **41**:544, 2009
84. Hanahan D, Weinberg RA: The hallmarks of cancer. *Cell* **100**:57, 2000
85. Lengauer C, Kinzler KW, Vogelstein B: Genetic instabilities in human cancers. *Nature* **396**:643, 1998
86. Glick AB, Yuspa SH: Tissue homeostasis and the control of the neoplastic phenotype in epithelial cancers. *Semin Cancer Biol* **15**:75, 2005
87. Kemp CJ: Multistep skin cancer in mice as a model to study the evolution of cancer cells. *Semin Cancer Biol* **15**:460, 2005
88. Yuspa SH: The pathogenesis of squamous cell cancer: Lessons learned from studies of skin carcinogenesis—Thirty-third G.H.A. Clowes Memorial Award Lecture. *Cancer Res* **54**:1178, 1994
89. Hennings H et al: Induction of papillomas with a high probability of conversion to malignancy. *Carcinogenesis* **6**:1607, 1985

90. Blume-Jensen P, Hunter T: Oncogenic kinase signalling. *Nature* **411**:355, 2001
91. Mueller MM: Inflammation in epithelial skin tumours: Old stories and new ideas. *Eur J Cancer* **42**:735, 2006
92. Iversen OH: The skin tumorigenic and carcinogenic effects of different doses, numbers of dose fractions and concentrations of 7,12-dimethylbenz[a]anthracene in acetone applied on hairless mouse epidermis. Possible implications for human carcinogenesis. *Carcinogenesis* **12**:493, 1991
93. Hennings H et al: Development of an *in vitro* analogue of initiated mouse epidermis to study tumor promoters and antipromoters. *Cancer Res* **50**:4794, 1990
94. Hennings H et al: Enhanced malignant conversion of benign mouse skin tumors by cisplatin. *J Natl Cancer Inst* **82**:836, 1990
95. Kemp CJ, Fee F, Balmain A: Allelotype analysis of mouse skin tumors using polymorphic microsatellites: Sequential genetic alterations on chromosomes 6, 7, and 11. *Cancer Res* **53**:6022, 1993
96. Robertson KD, Jones PA: DNA methylation: Past, present and future directions. *Carcinogenesis* **21**:461, 2000
97. Zackheim HS: Experimental basal cell carcinoma in the rat. In: *Models in Dermatology*, edited by L Maibach. Basel, Karger, 1985, p. 89
98. Johnson WD et al: Dehydroretronecine-induced skin tumors in mice. *J Natl Cancer Inst* **61**:85, 1978
99. Tschen JP et al: Pleomorphic basal cell carcinoma: Case reports and review. *South Med J* **99**:296, 2006
100. Sneddon JB et al: Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. *Proc Natl Acad Sci U S A* **103**:14842, 2006
101. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. *Annu Rev Cell Dev Biol* **17**:463, 2001
102. Bigelow RL et al: Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1. *J Biol Chem* **279**:1197, 2004
103. Regl G et al: Activation of the BCL2 promoter in response to Hedgehog/GLI signal transduction is predominantly mediated by GLI2. *Cancer Res* **64**:7724, 2004
104. Ponten F et al: Epithelial-stromal interactions in basal cell cancer: The PDGF system. *J Invest Dermatol* **102**:304, 1994
105. Xie J et al: A role of PDGFRalpha in basal cell carcinoma proliferation. *Proc Natl Acad Sci U S A* **98**:9255, 2001
106. Kasper M et al: Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes. *Mol Cell Biol* **26**:6283, 2006
107. Fan H, Khavari PA: Sonic hedgehog opposes epithelial cell cycle arrest. *J Cell Biol* **147**:71, 1999
108. Barnes EA et al: Patched1 interacts with cyclin B1 to regulate cell cycle progression. *EMBO J* **20**:2214, 2001
109. Kenney AM, Rowitch DH: Sonic hedgehog promotes G(1) cyclin expression and sustained cell cycle progression in mammalian neuronal precursors. *Mol Cell Biol* **20**:9055, 2000
110. Mill P et al: Shh controls epithelial proliferation via independent pathways that converge on N-Myc. *Dev Cell* **9**:293, 2005
111. Yang SH et al: Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/beta3-catenin signaling. *Nat Genet* **40**:1130, 2008
112. Angel JM, Caballero M, DiGiovanni J: Identification of novel genetic loci contributing to 12-O-tetradecanoylphorbol-13-acetate skin tumor promotion susceptibility in DBA/2 and C57BL/6 mice. *Cancer Res* **63**(11):2747-2751, 2003 PubMed PMID: 12782578.
113. Mock BA et al: Multigenic control of skin tumor susceptibility in SENCARA/Pt mice. *Carcinogenesis* **19**(6):1109-1115, 1998 PubMed PMID: 9667751.
114. Mahler KL et al: Sequence divergence of Mus spretus and Mus musculus across a skin cancer susceptibility locus. *BMC Genomics* **9**:626, 2008 PubMed PMID: 19105829; PubMed Central PMCID: PMC2628916.
115. Wakabayashi Y et al: Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice. *Nature* **445**(7129):761-765, 2007 Epub 2007 Jan 17. PubMed PMID: 17230190.
116. Dominey AM et al: Targeted overexpression of transforming growth factor alpha in the epidermis of transgenic mice elicits hyperplasia, hyperkeratosis, and spontaneous squamous papillomas. *Cell Growth Differ* **4**:1071, 1993

117. Vassar R, Hutton ME, Fuchs E: Transgenic overexpression of transforming growth factor α bypasses the need for c-Ha-ras mutations in mouse skin tumorigenesis. *Mol Cell Biol* 12:4643, 1992
118. Hansen LA et al: The epidermal growth factor receptor is required to maintain the proliferative population in the basal compartment of epidermal tumors. *Cancer Res* 60:3328, 2000
119. Sabilia M et al: The EGF receptor provides an essential survival signal for SOS- dependent skin tumor development. *Cell* 102:211, 2000
120. Kiguchi K et al: Constitutive expression of erbB2 in epidermis of transgenic mice results in epidermal hyperproliferation and spontaneous skin tumor development. *Oncogene* 19:4243, 2000
121. DiGiovanni J et al: Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumor promotion. *Cancer Res* 60:1561, 2000
122. Skobe M, Fusenig NE: Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. *Proc Natl Acad Sci U S A* 95:1050, 1998
123. Pierce AM et al: Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. *Proc Natl Acad Sci U S A* 95:8858, 1998
124. Robles AI et al: Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo. *Genes Dev* 12:2469, 1998
125. Rane SG et al: Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. *Mol Cell Biol* 22:644, 2002
126. Guasch G et al: Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. *Cancer Cell* 12:313, 2007
127. Hoot KE et al: Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression. *J Clin Invest* 118:2722, 2008
128. Harradine KA et al: Elevated cutaneous Smad activation associates with enhanced skin tumor susceptibility in organ transplant recipients. *Clin Cancer Res* 15:5101, 2009
129. Reddig PJ et al: Transgenic mice overexpressing protein kinase Cdelta in the epidermis are resistant to skin tumor promotion by 12-O-tetradecanoylphorbol-13- acetate. *Cancer Res* 59:5710, 1999
130. Jansen AP et al: Protein kinase C-epsilon transgenic mice: A unique model for metastatic squamous cell carcinoma. *Cancer Res* 61:808, 2001
131. Gonzalez-Suarez E et al: Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. *Nat Genet* 26:114, 2000
132. Pelengaris S et al: Reversible activation of c-Myc in skin: Induction of a complex neoplastic phenotype by a single oncogenic lesion. *Mol Cell* 3:565, 1999
133. Waikel RL et al: Deregulated expression of c-Myc depletes epidermal stem cells. *Nat Genet* 28:165, 2001
134. Missero C et al: The absence of p21^{Cip1/WAF1} alters keratinocyte growth and differentiation and promotes ras-tumor progression. *Genes Dev* 10:3065, 1996
135. Weinberg WC et al: Genetic deletion of p21^{WAF1} enhances papilloma formation but not malignant conversion in experimental mouse skin carcinogenesis. *Cancer Res* 59:2050, 1999
136. Glick AB et al: Targeted deletion of the TGF- β 1 gene causes rapid progression to squamous cell carcinoma. *Genes Dev* 8:2429, 1994
137. Go C, Li P, Wang XJ: Blocking transforming growth factor β signaling in transgenic epidermis accelerates chemical carcinogenesis: A mechanism associated with increased angiogenesis. *Cancer Res* 59:2861, 1999
138. Portella G et al: Transforming growth factor β is essential for spindle cell conversion of mouse skin carcinoma in vivo: Implications for tumor invasion. *Cell Growth Differ* 9:393, 1998
139. Han G et al: Distinct mechanisms of TGF- β 1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. *J Clin Invest* 115:1714, 2005
140. Perez-Lorenzo R et al: Transforming growth factor β 1 enhances tumor promotion in mouse skin carcinogenesis. *Carcinogenesis* 31:1116, 2010
141. Young MR et al: Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. *Proc Natl Acad Sci U S A* 96:9827, 1999
142. Saez E et al: c-fos is required for malignant progression of skin tumors. *Cell* 82:721, 1995
143. Gerdes MJ et al: Activator protein-1 activity regulates epithelial tumor cell identity. *Cancer Res* 66:7578, 2006
144. Clifford A et al: Role of ornithine decarboxylase in epidermal tumorigenesis. *Cancer Res* 55:1680, 1995

145. Linardopoulos S et al: Deletion and altered regulation of *p16INK4a* and *p15INK4b* in undifferentiated mouse skin tumors. *Cancer Res* **55**:5168, 1995
146. Navarro P et al: A role for the E-cadherin cell-cell adhesion molecule during tumor progression of mouse epidermal carcinogenesis. *J Cell Biol* **115**:517, 1991
147. Chan KS et al: Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. *J Clin Invest* **114**:720, 2004
148. Oskarsson T et al: Skin epidermis lacking the c-Myc gene is resistant to Ras-driven tumorigenesis but can reacquire sensitivity upon additional loss of the p21Cip1 gene. *Genes Dev* **20**:2024, 2006
149. Proweller A et al: Impaired notch signaling promotes de novo squamous cell carcinoma formation. *Cancer Res* **66**:7438, 2006
150. Kobiela A, Fuchs E: Links between alpha-catenin, NF-kappaB, and squamous cell carcinoma in skin. *Proc Natl Acad Sci U S A* **103**:2322, 2006
151. Budunova IV et al: Increased expression of p50-NF-kappaB and constitutive activation of NF-kappaB transcription factors during mouse skin carcinogenesis. *Oncogene* **18**:7423, 1999
152. Li AG et al: Smad3 knockout mice exhibit a resistance to skin chemical carcinogenesis. *Cancer Res* **64**:7836, 2004
153. Nagase H et al: Distinct genetic loci control development of benign and malignant skin tumours in mice. *Nat Genet* **10**:424, 1995
154. Nagase H, Mao JH, Balmain A: A subset of skin tumor modifier loci determines survival time of tumor-bearing mice. *Proc Natl Acad Sci U S A* **96**:15032, 1999
155. Quigley D, Balmain A: Systems genetics analysis of cancer susceptibility: From mouse models to humans. *Nat Rev Genet* **10**:651, 2009
156. Ewart-Toland A et al: Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. *Nat Genet* **34**:403, 2003
157. Long DJ et al: NAD(P)H:quinone oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. *Cancer Res* **60**:5913, 2000
158. Girardi M et al: Regulation of cutaneous malignancy by gammadelta T cells. *Science* **294**:605, 2001
159. Nelson H et al: The XRCC1 Arg399Gln polymorphism, sunburn, and non-melanoma skin cancer: Evidence of gene-environment interaction. *Cancer Res* **62**:152, 2002
160. Lear JT et al: Detoxifying enzyme genotypes and susceptibility to cutaneous malignancy. *Br J Dermatol* **142**:8, 2000
161. Ramachandran S et al: Susceptibility and modifier genes in cutaneous basal cell carcinomas and their associations with clinical phenotype. *J Photochem Photobiol B* **63**:1, 2001
162. Ljungman M: Individual variation in p53 responsiveness. *J Natl Cancer Inst* **93**:82, 2001
163. Wright TI, Spencer JM, Flowers FP: Chemoprevention of nonmelanoma skin cancer. *J Am Acad Dermatol* **54**:933, 2006
164. Fischer SM et al: Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. *Mol Carcinog* **25**:231, 1999
165. Takigawa M et al: Inhibition of mouse skin tumor promotion and of promoter-stimulated epidermal polyamine biosynthesis by -difluoromethylornithine. *Cancer Res* **43**:3732, 1983
166. Harwood CA et al: Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: a 16-year retrospective study. *Arch Dermatol* **141**:456-464, 2005
167. Darwiche N et al: Mouse skin tumor progression results in differential expression of retinoic acid and retinoid X receptors. *Cancer Res* **55**:2774, 1995
168. Xu XC et al: Progressive decreases in nuclear retinoid receptors during skin squamous carcinogenesis. *Cancer Res* **61**:4306, 2001
169. Birt DF et al: High-fat diet blocks the inhibition of skin carcinogenesis and reductions in protein kinase C by moderate energy restriction. *Mol Carcinog* **16**:115, 1996
170. Black HS et al: Effect of a low-fat diet on the incidence of actinic keratosis. *N Engl J Med* **330**:1272, 1994
171. Gupta S, Mukhtar H: Chemoprevention of skin cancer through natural agents. *Skin Pharmacol Appl Skin Physiol* **14**:373, 2001
172. Eklind J et al: Imiquimod to treat different cancers of the epidermis. *Dermatol Surg* **29**:890, 2003
173. Yarosh D et al: Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: A randomised study. Xeroderma Pigmentosum Study Group. *Lancet* **357**:926, 2001

174. Flaherty KT et al: Inhibition of mutated, activated BRAF in metastatic melanoma. *N Engl J Med* **363**:809, 2010
175. Taipale J et al: Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. *Nature* **406**:1005, 2000
176. Scales SJ, de Sauvage FJ: Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. *Trends Pharmacol Sci* **30**:303, 2009
177. Von Hoff DD et al: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. *N Engl J Med* **361**:1164, 2009
178. Dlugosz AA, Talpaz M: Following the hedgehog to new cancer therapies. *N Engl J Med* **361**:1202, 2009

